Baseline hepatocyte ballooning is a risk factor for adverse events in patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease

Figure 1 Flow chart of patient screening and grouping. CHB: Chronic hepatitis B; NAFLD: Nonalcoholic fatty liver disease; HIV: Human immunodeficiency virus; AIH: Autoimmune hepatitis; PBC: Primary biliary cholangitis.

Figure 2 Kaplan-Meier survival analysis of nonalcoholic fatty liver disease and the risk of cirrhosis. A: Results of the Kaplan-Meier (K-M) survival analysis of the risk of cirrhosis after propensity score matching (PSM) in nonalcoholic fatty liver disease (NAFLD) and non NAFLD with chronic hepatitis B; B: Results of K-M survival analysis of the risk of cirrhosis after PSM in patients with mild fibrosis and in those with severe fibrosis; C: Nonalcoholic steatohepatitis (NASH) and non-NASH stratification of NAFLD and K-M survival analysis of the risk of cirrhosis. NAFLD: Nonalcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis; PSM: Propensity score matching.

Figure 3 Kaplan-Meier survival analysis of hepatocellular carcinoma risk. A: Results of the Kaplan-Meier (K-M) survival analysis of the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B and nonalcoholic fatty liver disease (NAFLD) and those without NAFLD; B: Results of K-M survival analysis of the risk of HCC in patients with mild fibrosis and those with severe fibrosis; C: Nonalcoholic steatohepatitis (NASH) and non-NASH stratification of NAFLD and K-M survival analysis of the risk of HCC; D: Ballooning and non-ballooning stratification of NAFLD and K-M survival analysis of the risk of HCC. NAFLD: Nonalcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis; HCC: Hepatocellular carcinoma.